|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
154,660,000 |
Market
Cap: |
162.39(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.429 - $1.75 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Adaptimmune Therapeutics is a biopharmaceutical company focused on developing T-cell therapies for solid tumors. Co.'s proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors against those targets, and produce therapeutic candidates (SPEAR T-cells) for administration to patients. Co. has clinical trials on its ADP-A2M4, ADP-A2M4CD8, each targeting the MAGE-A4 antigen, and ADP-A2AFP SPEAR T-cells targeting the alpha fetoprotein (AFP) cancer antigen in solid tumor types including non-small cell lung cancer, head and neck cancer, ovarian, urothelial, melanoma, and hepatocellular.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
165,799 |
218,930 |
354,372 |
Total Sell Value |
$0 |
$124,385 |
$172,782 |
$411,912 |
Total People Sold |
0 |
4 |
5 |
6 |
Total Sell Transactions |
0 |
16 |
19 |
41 |
End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Rawcliffe Adrian |
Chief Executive Officer |
|
2022-01-12 |
4 |
S |
$3.54 |
$10,795 |
D/D |
(3,046) |
3,356 |
|
56% |
|
Norry Elliot |
Chief Medical Officer |
|
2022-01-12 |
4 |
S |
$3.54 |
$3,027 |
D/D |
(854) |
1,383 |
|
56% |
|
Lunger John |
Chief Patient Supply Officer |
|
2022-01-12 |
4 |
S |
$3.54 |
$3,813 |
D/D |
(1,076) |
1,749 |
|
56% |
|
Bertrand William C Jr |
Chief Operating Officer |
|
2022-01-11 |
4 |
S |
$3.56 |
$13,409 |
D/D |
(3,770) |
6,343 |
|
54% |
|
Rawcliffe Adrian |
Chief Executive Officer |
|
2022-01-11 |
4 |
S |
$3.56 |
$51,081 |
D/D |
(14,362) |
15,978 |
|
54% |
|
Norry Elliot |
Chief Medical Officer |
|
2022-01-11 |
4 |
S |
$3.56 |
$13,409 |
D/D |
(3,770) |
6,343 |
|
54% |
|
Lunger John |
Chief Patient Supply Officer |
|
2022-01-11 |
4 |
S |
$3.56 |
$13,409 |
D/D |
(3,770) |
6,343 |
|
54% |
|
Norry Elliot |
Chief Medical Officer |
|
2022-01-04 |
4 |
S |
$4.06 |
$3,451 |
D/D |
(849) |
1,388 |
|
63% |
|
Lunger John |
Chief Patient Supply Officer |
|
2022-01-04 |
4 |
S |
$4.06 |
$4,349 |
D/D |
(1,070) |
1,755 |
|
63% |
|
Rawcliffe Adrian |
Chief Executive Officer |
|
2022-01-04 |
4 |
S |
$4.06 |
$22,483 |
D/D |
(5,532) |
6,172 |
|
63% |
|
Bertrand William C Jr |
Chief Operating Officer |
|
2022-01-04 |
4 |
S |
$4.06 |
$14,184 |
D/D |
(3,490) |
5,873 |
|
63% |
|
Rawcliffe Adrian |
Chief Executive Officer |
|
2021-09-01 |
4 |
S |
$5.20 |
$14,452 |
D/D |
(2,782) |
3,070 |
|
32% |
|
Lunger John |
Chief Patient Supply Officer |
|
2021-08-02 |
4 |
S |
$3.58 |
$10,536 |
D/D |
(2,939) |
4,873 |
|
-3% |
|
Lunger John |
Chief Patient Supply Officer |
|
2021-07-02 |
4 |
S |
$4.26 |
$8,133 |
D/D |
(1,907) |
3,170 |
|
-28% |
|
Bertrand William C Jr |
Chief Operating Officer |
|
2021-07-02 |
4 |
S |
$4.26 |
$18,659 |
D/D |
(4,375) |
7,329 |
|
-28% |
|
Rawcliffe Adrian |
Chief Executive Officer |
|
2021-06-28 |
4 |
S |
$4.37 |
$12,210 |
D/D |
(2,794) |
3,058 |
|
-24% |
|
Alleva Lawrence M |
Director |
|
2021-06-01 |
4 |
B |
$0.79 |
$9,954 |
I/I |
12,600 |
12,600 |
2.1 |
7% |
|
Tayton-Martin Helena Katrina |
Chief Business Officer |
|
2021-03-03 |
4 |
OE |
$0.16 |
$280,245 |
D/D |
1,785,000 |
1,800,000 |
|
- |
|
Norry Elliot |
Chief Medical Officer |
|
2021-01-19 |
4 |
S |
$5.67 |
$11,968 |
D/D |
(2,111) |
3,539 |
|
15% |
|
Lunger John |
Chief Patient Supply Officer |
|
2021-01-19 |
4 |
S |
$5.67 |
$24,708 |
D/D |
(4,358) |
7,346 |
|
15% |
|
Rawcliffe Adrian |
Chief Executive Officer |
|
2021-01-19 |
4 |
S |
$5.67 |
$56,009 |
D/D |
(9,879) |
13,529 |
|
15% |
|
Bertrand William C Jr |
Chief Operating Officer |
|
2021-01-12 |
4 |
S |
$6.15 |
$13,744 |
D/D |
(2,234) |
3,768 |
|
14% |
|
Lunger John |
Chief Patient Supply Officer |
|
2021-01-12 |
4 |
S |
$6.15 |
$6,509 |
D/D |
(1,058) |
1,767 |
|
14% |
|
Rawcliffe Adrian |
Chief Executive Officer |
|
2021-01-12 |
4 |
S |
$6.15 |
$16,654 |
D/D |
(2,707) |
3,695 |
|
14% |
|
Norry Elliot |
Chief Medical Officer |
|
2021-01-12 |
4 |
S |
$6.15 |
$5,174 |
D/D |
(841) |
1,396 |
|
14% |
|
234 Records found
|
|
Page 3 of 10 |
|
|